Solutions Overview

Today’s cancer treatments are varied, complicated and costly. Oncology Analytics provides the critical missing link between health plans and providers: access to current, evidence-based, disease-specific analytics on all cancer types and treatment options.

Solutions that Put Patients First

It has been estimated that oncologists would need 29 hours a day to keep up with the research and findings of new cancer treatments that enter the market each day. Oncology Analytics relieves this burden through a combination of technology-enabled services, supported by our dedicated clinical team of board-certified oncology physicians and pharmacists.

e-Prior Authorization

Oncology Analytics e-Prior Authorization platform is purpose-built for oncology to efficiently evaluate and approve high-quality and high-value treatments for cancer care.
Read More

Specialty Oncology Case Review

For complex and complicated patient cases, the Oncology Analytics’ Clinical Team facilitates peer-to-peer reviews in which the efficacy of the recommended cancer treatment is always prioritized over the cost of therapy.
Read More

Cancer Care Insights & Analytics

Oncology Analytics offers deep insights and analytics for health plans and providers, helping to drive further development and improvement of cancer care.
Read More

e-Prior Authorization

Oncology Analytics e-Prior Authorization platform is purpose-built for oncology to efficiently evaluate and approve high-quality and high-value treatments for cancer care.

Used by physicians to support over 4.3 million health plan members in the US and Puerto Rico, the Oncology Analytics e-Prior Authorization platform covers the full spectrum of therapeutics, across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care.

Using a simple user interface, physicians enter their treatment recommendation and receive an automatic authorization if their request lies within recognized guidelines.

Treatments requested that are outside of the guidelines receive a further review from the Oncology Analytics Clinical Oncology Team. The Clinical Oncology Team then collaborates with the physicians to ensure that the treatment is optimized to the individual patient. Ninety percent of treatment requests are approved automatically or with limited follow up.

All treatment protocols contained within the e-Prior Authorization platform are reviewed and scored by our Clinical Oncology Team for efficacy, toxicity, and affordability. New indications for treatment approved by the FDA and newly published cancer research are immediately entered into the system.

Oncology Analytics has proven that evidence-based medicine works in the delivery of efficacious and affordable cancer care.

Otis Brawley, MD
Former Chief Medical & Scientific Officer, Executive VP, American Cancer Society

Specialty Oncology Case Review

For complex patient cases, our Clinical Oncology Team facilitates peer-to-peer reviews which may include in-depth reviews by our Distinguished Academic Advisory Board.

Treating oncologists have the opportunity to engage in peer-to-peer discussions of patient cases with Oncology Analytics’ board-certified oncologists, radiation oncologists, hematologists, and pharmacists, to ensure the recommended therapy is the most efficacious, affordable and least toxic and provides the best evidence-based potential outcome.

Specialty Oncology Case Reviews provide a guaranteed “second opinion” for the patient. We recognize that sometimes costly treatments represent the best quality of patient care. However, in many cases there are often less costly and equally efficacious alternatives. In addition, Specialty Oncology Case Reviews can potentially identify additional cancer treatment options, such as clinical trials or compassionate use, which may not be readily apparent.

I am amazed how Oncology Analytics manages difficult cases with varying existing scientific opinions. They have proven to me that they always have the patient’s best interest in mind. I personally would like to thank OA in the name of my patient.

Izidore Lossos, MD
Oncologist, University of Miami Sylvester Cancer Center

Cancer Care Insights & Analytics

Aggregating oncology data from multiple sources is a difficult task for health plans. Gaining immediate, actionable insights from the data is even more challenging. Oncology Analytics enables health plans with analytics, reports and advisory services, which provide both deep strategic business insights and personalized treatment evaluations for members that balance efficacy, toxicity and cost.


Oncology Insights leverages data science, predictive analytic models and machine learning to provide clarity on treatment efficacy, quality, and costs to help health plans determine which treatments are in the best interests of their members, sequenced at the right time.

Oncology Insights is built on three key foundational pillars, real-world data, comparative benchmarking, and advisory services.

  • Real-World Data. Oncology Insights applies leading-edge natural language processing capabilities to ingest clinical notes, lab reports, radiology scan results, and chemotherapy regimen data to help health plans better understand outcomes for each member.
  • Comparative Benchmarking. Oncology Insights utilizes HIPAA compliant methods to de-identify the data to enable health plans to compare their performance against other similar organizations in areas like oncology drug spend, drug trend, and network provider prescribing patterns.
  • Advisory Services. By using Oncology Insights, health plans get access to a multi-disciplinary advisory team, consisting of board-certified oncology pharmacists and clinical analysts, who help interpret the data and surface immediate actionable insights. This approach lessens health plans’ burden of managing multiple data sources and ensures their focus on strategic areas that will have the greatest impact on their members.

Through Oncology Reports, health plans gain deep analytic insights into key business areas such as oncology drug spend, disease assignments, the latest drug trends in their population, and insights into their provider network efficiency.

Our Oncology Network Management report objectively scores providers and groups for overall oncology drug utilization, performance against set pathways, and responsiveness to metrics that are important to the health plan.

The Oncology Analytics Quality Quotient Score demonstrates a provider’s adherence to

  • Preference for health plan protocols that are backed by strong scientific evidence and national guidelines recommendations
  • Preference for protocols with higher efficacy, lesser toxicity, and better affordability compared to other protocols of the same indication

Two-thirds of men with low-risk prostate cancer are over-treated. Oncology Analytics uses the latest Epstein criteria to help urologists to decide which early-stage prostate cancer patients may be appropriate candidates for active surveillance rather than surgery or radiotherapy.

Jonathan Epstein, MD
Pathologist, Johns Hopkins Hospital

Subscribe To Our Newsletter

Join our monthly mailing list to receive the latest news and updates from Oncology Analytics.

You have Successfully Subscribed!